The primary objective of this study was to evaluate the change in serum interferon gamma and Interleukin-15 levels before and after use of oral drug baricitinib therapy. Venous blood samples (5 mL) were collected from each participant at baseline and at six months.

Changes at baseline and immediately after 6 mmonths will be analyzed, primary outcome is the changes in serum levels over 6 months, while secondary outcome is changes in the Severity of Alopecia Tool (SALT score) over 6 months.

Inclusion Criteria:

• Adults diagnosed clinically with Alopecia Areata.
• Severity of alopecia tool (SALT) score greater than 50.
• Only patients with disease duration exceeding six months but less than eight years will be included.

Exclusion Criteria:

• Patients were excluded if they were pregnant or lactating, and had chronic hepatic or renal disease.
• Cases diagnosed with malignancy, scalp infections, or other types of alopecia will also excluded from the current study.
• Recent use of systemic treatment within the last 3 months or topical treatment within the last 4 weeks also will be excluded.

Data is avialable upon request from the principal investigator.